Logo image of PSTV

PLUS THERAPEUTICS INC (PSTV) Stock Fundamental Analysis

NASDAQ:PSTV - Nasdaq - US72941H5090 - Common Stock - Currency: USD

0.3089  -0.01 (-1.62%)

After market: 0.307 0 (-0.62%)

Fundamental Rating

1

Overall PSTV gets a fundamental rating of 1 out of 10. We evaluated PSTV against 557 industry peers in the Biotechnology industry. PSTV may be in some trouble as it scores bad on both profitability and health. While showing a medium growth rate, PSTV is valued expensive at the moment.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

PSTV had negative earnings in the past year.
PSTV had a negative operating cash flow in the past year.
PSTV had negative earnings in each of the past 5 years.
In the past 5 years PSTV always reported negative operating cash flow.
PSTV Yearly Net Income VS EBIT VS OCF VS FCFPSTV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -5M -10M -15M -20M -25M

1.2 Ratios

PSTV has a Return On Assets of -224.93%. This is amonst the worse of the industry: PSTV underperforms 90.66% of its industry peers.
Industry RankSector Rank
ROA -224.93%
ROE N/A
ROIC N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
PSTV Yearly ROA, ROE, ROICPSTV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 500 -500

1.3 Margins

PSTV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
PSTV Yearly Profit, Operating, Gross MarginsPSTV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -2K -4K -6K -8K

More info and screens

1

2. Health

2.1 Basic Checks

PSTV does not have a ROIC to compare to the WACC, probably because it is not profitable.
PSTV has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, PSTV has more shares outstanding
Compared to 1 year ago, PSTV has a worse debt to assets ratio.
PSTV Yearly Shares OutstandingPSTV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 1M 2M 3M 4M 5M
PSTV Yearly Total Debt VS Total AssetsPSTV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M

2.2 Solvency

PSTV has an Altman-Z score of -62.86. This is a bad value and indicates that PSTV is not financially healthy and even has some risk of bankruptcy.
PSTV's Altman-Z score of -62.86 is on the low side compared to the rest of the industry. PSTV is outperformed by 94.97% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -62.86
ROIC/WACCN/A
WACC5.82%
PSTV Yearly LT Debt VS Equity VS FCFPSTV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 10M -10M -20M

2.3 Liquidity

PSTV has a Current Ratio of 1.03. This is a normal value and indicates that PSTV is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Current ratio, with a value of 1.03, PSTV is doing worse than 87.61% of the companies in the same industry.
PSTV has a Quick Ratio of 1.03. This is a normal value and indicates that PSTV is financially healthy and should not expect problems in meeting its short term obligations.
The Quick ratio of PSTV (1.03) is worse than 86.36% of its industry peers.
Industry RankSector Rank
Current Ratio 1.03
Quick Ratio 1.03
PSTV Yearly Current Assets VS Current LiabilitesPSTV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 5M 10M 15M 20M

More info and screens

4

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 17.92% over the past year.
PSTV shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -14.37%.
Measured over the past years, PSTV shows a decrease in Revenue. The Revenue has been decreasing by -3.61% on average per year.
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.67%
Revenue 1Y (TTM)-14.37%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-36.85%

3.2 Future

PSTV is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 25.24% yearly.
PSTV is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 102.09% yearly.
EPS Next Y59.93%
EPS Next 2Y28.08%
EPS Next 3Y23.44%
EPS Next 5Y25.24%
Revenue Next Year19.43%
Revenue Next 2Y14.01%
Revenue Next 3Y87.71%
Revenue Next 5Y102.1%

3.3 Evolution

The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
PSTV Yearly Revenue VS EstimatesPSTV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M 400M
PSTV Yearly EPS VS EstimatesPSTV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 -500K -1M -1.5M -2M -2.5M

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

PSTV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for PSTV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
PSTV Price Earnings VS Forward Price EarningsPSTV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
PSTV Per share dataPSTV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 -0.5 -1 -1.5 -2 -2.5

4.3 Compensation for Growth

A more expensive valuation may be justified as PSTV's earnings are expected to grow with 23.44% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y28.08%
EPS Next 3Y23.44%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for PSTV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

PLUS THERAPEUTICS INC

NASDAQ:PSTV (6/16/2025, 8:01:06 PM)

After market: 0.307 0 (-0.62%)

0.3089

-0.01 (-1.62%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)05-30 2025-05-30/amc
Earnings (Next)08-12 2025-08-12/amc
Inst Owners3.9%
Inst Owner Change-42.62%
Ins Owners0.3%
Ins Owner Change0%
Market Cap5.25M
Analysts80
Price Target10.03 (3147.01%)
Short Float %3.68%
Short Ratio0.07
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-346.08%
Min EPS beat(2)-695.44%
Max EPS beat(2)3.28%
EPS beat(4)2
Avg EPS beat(4)-165.06%
Min EPS beat(4)-695.44%
Max EPS beat(4)35.51%
EPS beat(8)6
Avg EPS beat(8)-65.25%
EPS beat(12)7
Avg EPS beat(12)-50.89%
EPS beat(16)8
Avg EPS beat(16)-39.2%
Revenue beat(2)1
Avg Revenue beat(2)3.74%
Min Revenue beat(2)-30.01%
Max Revenue beat(2)37.49%
Revenue beat(4)1
Avg Revenue beat(4)-5.89%
Min Revenue beat(4)-30.01%
Max Revenue beat(4)37.49%
Revenue beat(8)3
Avg Revenue beat(8)14.9%
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)2.16%
PT rev (3m)-4.07%
EPS NQ rev (1m)25.42%
EPS NQ rev (3m)52.69%
EPS NY rev (1m)0%
EPS NY rev (3m)42.79%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)-12.5%
Revenue NY rev (1m)0%
Revenue NY rev (3m)34.78%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 1.01
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-2.61
EYN/A
EPS(NY)-0.78
Fwd EYN/A
FCF(TTM)-0.76
FCFYN/A
OCF(TTM)-0.72
OCFYN/A
SpS0.31
BVpS-1.39
TBVpS-1.44
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -224.93%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-132.52%
ROA(5y)-105.31%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score3
Asset Turnover0.43
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 91.6%
Cap/Sales 12.56%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.03
Quick Ratio 1.03
Altman-Z -62.86
F-Score3
WACC5.82%
ROIC/WACCN/A
Cap/Depr(3y)67.77%
Cap/Depr(5y)74.15%
Cap/Sales(3y)82.31%
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)17.92%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-58.67%
EPS Next Y59.93%
EPS Next 2Y28.08%
EPS Next 3Y23.44%
EPS Next 5Y25.24%
Revenue 1Y (TTM)-14.37%
Revenue growth 3YN/A
Revenue growth 5Y-3.61%
Sales Q2Q%-36.85%
Revenue Next Year19.43%
Revenue Next 2Y14.01%
Revenue Next 3Y87.71%
Revenue Next 5Y102.1%
EBIT growth 1Y-25.49%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year8.2%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y15.13%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y17.92%
OCF growth 3YN/A
OCF growth 5YN/A